Omeros Corp OMER
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $3.92
- Day Range
- $3.86–4.02
- 52-Week Range
- $0.92–5.68
- Bid/Ask
- $3.60 / $4.19
- Market Cap
- $227.15 Mil
- Volume/Avg
- 139,417 / 328,199
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 2.05%
Company Profile
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 198
- Website
- https://www.omeros.com
Comparables
Valuation
|
Metric
|
OMER
|
SWTX
|
PTCT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 4.31 | — |
Price/Sales | — | 25.81 | 3.17 |
Price/Cash Flow | — | — | — |
Price/Earnings
OMER
SWTX
PTCT
Financial Strength
|
Metric
|
OMER
|
SWTX
|
PTCT
|
|---|---|---|---|
Quick Ratio | 3.31 | 7.49 | 2.10 |
Current Ratio | 3.41 | 7.91 | 2.23 |
Interest Coverage | −5.61 | — | −2.15 |
Quick Ratio
OMER
SWTX
PTCT
Profitability
|
Metric
|
OMER
|
SWTX
|
PTCT
|
|---|---|---|---|
Return on Assets (Normalized) | −43.94% | −32.86% | −15.67% |
Return on Equity (Normalized) | — | −37.78% | — |
Return on Invested Capital (Normalized) | −75.82% | −42.13% | −102.66% |
Return on Assets
OMER
SWTX
PTCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vdpdrkhdl | Jjdbz | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hbsrxxlhx | Xcfncqd | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jzhmszgn | Xdtjl | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zxjmxnjhr | Nvwqgh | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Stthylk | Qhq | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Svwvdtwz | Grbqn | $28.1 Bil | |||
| Moderna Inc
MRNA
| Hvppkyhkh | Xvjj | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Fdydngpk | Sxq | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yxmrljhg | Pqlwdj | $13.4 Bil | |||
| Incyte Corp
INCY
| Cztwtjmrj | Dcybmqh | $12.7 Bil |
United States